GlassScriptPhysician profile
Mary Gaffney
NPI 1467569483
$8,451.31
in general payments reported to CMS, 2019-2025
34 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,264 · 2020: $555 · 2021: $963 · 2022: $884 · 2023: $1,085 · 2024: $1,085 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.82 |
| Education | $267.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,823.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Astrazeneca Uk Limited | $1,494.50 | 2019 | |
| Lilly USA, LLC | $758.26 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $539.29 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $494.71 | 2025 | Austedo Xr |
| Novo Nordisk INC | $471.92 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $455.53 | 2021 | |
| Indivior INC. | $448.74 | 2019-2025 | Sublocade |
| Orexo US, INC. | $350.97 | 2023-2025 | Zubsolv |
| Amgen INC. | $306.40 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $262.21 | 2022-2024 | |
| Pfizer INC. | $191.24 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $191.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $103.37 | 2019-2022 | |
| Medtronic, INC. | $90.44 | 2021-2025 | Minimed 780g |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $46.86 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.71 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $36.78 | 2022-2023 | Abilify Maintena, Rexulti |
| Glaxosmithkline, LLC. | $36.49 | 2022 | |
| Biowound Solutions, INC. | $36.09 | 2025 | Bio-Connekt |
| Shield Therapeutics INC | $35.88 | 2023-2024 | Accrufer |
| Vanda Pharmaceuticals INC. | $31.87 | 2022 | |
| Merck Sharp & Dohme LLC | $29.88 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $27.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.25 | 2019 | |
| Pear Therapeutics (US), INC. | $20.74 | 2022 | |
| Greer Laboratories, INC. | $17.41 | 2019 | |
| Alkermes, INC. | $16.75 | 2019 | |
| Dexcom, INC. | $16.31 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $14.74 | 2023 | Nexplanon |
| Gilead Sciences, INC. | $13.85 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.70 | 2023 | Nuzyra |
| Medtronic Minimed, INC. | $11.95 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Gaffney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.